NORTH AMERICA OPHTHALMIC DRUG MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • NORTH AMERICA OPHTHALMIC DRUG MARKET FORECAST 2019-2027

NORTH AMERICA OPHTHALMIC DRUG MARKET FORECAST 2019-2027

North America ophthalmic drugs market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 growing at a CAGR of 3.66% during the forecast period of 2019-2027. The ophthalmic drugs and devices market is driven by factors like increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.

NORTH AMERICA OPHTHALMIC DRUG MARKET FORECAST 2019-2027

North America Ophthalmic Drug Market by Indication (Dry Eye, Glaucoma, Infection/inflammation/allergy, Retinal Disorders, Other Indication) by Type (Prescription Drugs, Over-the-counter Drugs) by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Other Distribution Channel) by Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, Other Ophthalmic Drug Forms) by Therapeutic Class (Anti-glaucoma, Anti-infective, Anti-inflammatory, Anti-allergy) by Technology (Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small Molecule, Other Technology)

Request free sample

North America ophthalmic drugs market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 growing at a CAGR of 3.66% during the forecast period of 2019-2027. The ophthalmic drugs and devices market is driven by factors like increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.

The countries analyzed in the North America region are US and Canada. Globally increase in geriatric population, rise in a number of eye disorders, increase in healthcare expenditure and rise in adoption of minimally invasive surgeries have contributed to the growth of the ophthalmic drugs market. The prevalence of blindness and vision impairment and other eye-related disorders is expected to increase rapidly among all age group, gender and racial group in North America. However, few factors such as high market saturation, economic slowdown, drying pipelines and increasing competition are some of the factors hampering the potential of the North America ophthalmic drug market.

Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology. Some of the eminent market players operating are Merck & Co., Roche Holding AG, Pfizer Inc., Cipla Pharmaceuticals, GlaxoSmithKline, Senju Pharmaceutical Co., Ltd., Eyegate Pharmaceuticals, Valeant, Apollo Endosurgery, Allergan Inc., Regeneron, Abbott Laboratories, Novartis AG, Johnson and Johnson, Sun Pharmaceuticals Industries, Ltd., Bayer, and others.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • RETINAL DISORDERS ARE THE HIGHEST REVENUE GENERATING INDICATION
      • PRESCRIPTION DRUGS ARE THE FASTEST GROWING OPHTHALMIC DRUGS TYPE
      • HOSPITAL PHARMACIES ARE THE MAJORLY USED DISTRIBUTION CHANNEL
      • LIQUID OPHTHALMIC DRUG FORMS ARE THE WIDELY USED DOSAGE FORM
      • ANTI-ALLERGY THERAPEUTIC CLASS IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE DURING THE FORECAST PERIOD
      • SMALL MOLECULE TECHNOLOGY IS USED FOR THE TREATMENT OF EYE DISEASES
  1. MARKET DETERMINANTS
    • MARKET DEFINITION AND SCOPE
    • MARKET DRIVERS
      • INCREASING GERIATRIC POPULATION
      • TECHNOLOGICAL ADVANCEMENT
      • RISING PREVALENCE OF EYE DISORDERS
      • INCREASED HEALTHCARE EXPENDITURE
    • MARKET RESTRAINTS
      • RENOWNED DRUGS GOING OFF-PATENT
      • DELAY IN DRUG APPROVALS
    • MARKET OPPORTUNITIES
      • INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
      • GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
    • MARKET CHALLENGES
      • SIDE EFFECTS RELATED TO THE OPHTHALMIC DRUGS
  1. MARKET BY INDICATION
    • DRY EYE
    • GLAUCOMA
    • INFECTION/INFLAMMATION/ALLERGY
    • RETINAL DISORDERS
      • WET AGE-RELATED MACULAR DEGENERATION
      • DRY AGE-RELATED MACULAR DEGENERATION
      • DIABETIC RETINOPATHY
      • OTHER RETINAL DISORDERS
    • OTHER INDICATION
  2. MARKET BY TYPE
    • PRESCRIPTION DRUGS
    • OVER-THE-COUNTER DRUGS
  3. MARKET BY DISTRIBUTION CHANNEL
    • HOSPITAL PHARMACIES
    • DRUG STORES
    • ONLINE PHARMACIES
    • OTHER DISTRIBUTION CHANNEL
  4. MARKET BY DOSAGE FORM
    • LIQUID OPHTHALMIC DRUG FORMS
    • SOLID OPHTHALMIC DRUG FORMS
    • SEMISOLID OPHTHALMIC DRUG FORMS
    • MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
    • OTHER OPHTHALMIC DRUG FORMS
  5. MARKET BY THERAPEUTIC CLASS
    • ANTI-GLAUCOMA
    • ANTI-INFECTIVE
    • ANTI-INFLAMMATORY
    • ANTI-ALLERGY
  6. MARKET BY TECHNOLOGY
    • BIOLOGICS
    • CELL THERAPY
    • GENE THERAPY
    • DRUG DELIVERY
    • SMALL MOLECULE
    • OTHER TECHNOLOGY
  7. KEY ANALYTICS
    • PORTER’S FIVE FORCES ANALYSIS
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIER
      • THREATS OF NEW ENTRANTS
      • THREATS OF SUBSTITUTES
      • COMPETITIVE RIVALRY
    • VALUE CHAIN ANALYSIS
      • RESEARCH AND DEVELOPMENT
      • MANUFACTURING
      • MARKETING AND DISTRIBUTION
    • REGULATORY FRAMEWORK
    • OPPORTUNITY MATRIX
  8. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
  1. COMPANY PROFILES
    • ABBOTT LABORATORIES
    • ALLERGAN INC.
    • JOHNSON AND JOHNSON
    • BAYER
    • VALEANT
    • REGENERON
    • PFIZER INC.
    • MERCK & CO.
    • NOVARTIS AG
    • GLAXOSMITHKLINE
    • EYEGATE PHARMACEUTICALS
    • APOLLO ENDOSURGERY
    • ROCHE HOLDING AG
    • CIPLA PHARMACEUTICALS
    • SENJU PHARMACEUTICAL CO., LTD.
    • SUN PHARMACEUTICALS INDUSTRIES, LTD.

 

LIST OF TABLES

TABLE 1        NORTH AMERICA OPHTHALMIC DRUG MARKET REVENUE 2019-2027 ($ MILLION)

TABLE 2        COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY

TABLE 3        EYE DRUGS GONE OFF-PATENT

TABLE 4        NORTH AMERICA OPHTHALMIC DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)

TABLE 5        NORTH AMERICA DRY EYE MARKET 2019-2027 ($ MILLION)

TABLE 6        NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DRY EYE 2019-2027 ($ MILLION)

TABLE 7        NORTH AMERICA GLAUCOMA MARKET 2019-2027 ($ MILLION)

TABLE 8        NORTH AMERICA INFECTION/INFLAMMATION/ALLERGY MARKET 2019-2027 ($ MILLION)

TABLE 9        NORTH AMERICA RETINAL DISORDERS MARKET 2019-2027 ($ MILLION)

TABLE 10      NORTH AMERICA WET AGE-RELATED MACULAR DEGENERATION MARKET 2019-2027 ($ MILLION)

TABLE 11      NORTH AMERICA DRY AGE-RELATED MACULAR DEGENERATION MARKET 2019-2027 ($ MILLION)

TABLE 12      NORTH AMERICA DIABETIC RETINOPATHY MARKET 2019-2027 ($ MILLION)

TABLE 13      NORTH AMERICA OTHER RETINAL DISORDERS MARKET 2019-2027 ($ MILLION)

TABLE 14      NORTH AMERICA OTHER INDICATION MARKET 2019-2027 ($ MILLION)

TABLE 15      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE 16      NORTH AMERICA PRESCRIPTION DRUGS MARKET 2019-2027 ($ MILLION)

TABLE 17      NORTH AMERICA OVER-THE-COUNTER DRUGS MARKET 2019-2027 ($ MILLION)

TABLE 18      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)

TABLE 19      NORTH AMERICA HOSPITAL PHARMACIES MARKET 2019-2027 ($ MILLION)

TABLE 20      NORTH AMERICA DRUG STORES MARKET 2019-2027 ($ MILLION)

TABLE 21      NORTH AMERICA ONLINE PHARMACIES MARKET 2019-2027 ($ MILLION)

TABLE 22      NORTH AMERICA OTHER DISTRIBUTION CHANNEL MARKET 2019-2027 ($ MILLION)

TABLE 23      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DOSAGE FORM 2019-2027 ($ MILLION)

TABLE 24      NORTH AMERICA LIQUID OPHTHALMIC DRUG FORMS PHARMACIES MARKET 2019-2027 ($ MILLION)

TABLE 25      NORTH AMERICA SOLID OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)

TABLE 26      NORTH AMERICA SEMISOLID OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)

TABLE 27      NORTH AMERICA MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET 2019-2027 ($ MILLION)

TABLE 28      NORTH AMERICA OTHER OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)

TABLE 29      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY THERAPEUTIC CLASS 2019-2027 ($ MILLION)

TABLE 30      NORTH AMERICA ANTI-GLAUCOMA MARKET 2019-2027 ($ MILLION)

TABLE 31      NORTH AMERICA ANTI-INFECTIVE MARKET 2019-2027 ($ MILLION)

TABLE 32      NORTH AMERICA ANTI-INFLAMMATORY MARKET 2019-2027 ($ MILLION)

TABLE 33      NORTH AMERICA ANTI-ALLERGY MARKET 2019-2027 ($ MILLION)

TABLE 34      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)

TABLE 35      NORTH AMERICA BIOLOGICS MARKET 2019-2027 ($ MILLION)

TABLE 36      NORTH AMERICA CELL THERAPY MARKET 2019-2027 ($ MILLION)

TABLE 37      NORTH AMERICA GENE THERAPY MARKET 2019-2027 ($ MILLION)

TABLE 38      NORTH AMERICA DRUG DELIVERY MARKET 2019-2027 ($ MILLION)

TABLE 39      NORTH AMERICA SMALL MOLECULE MARKET 2019-2027 ($ MILLION)

TABLE 40      NORTH AMERICA OTHER TECHNOLOGY MARKET 2019-2027 ($ MILLION)

TABLE 41      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

 

LIST OF FIGURES

FIGURE 1      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY GLAUCOMA 2019-2027 ($ MILLION)

FIGURE 2      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY INFECTION /INFLAMMATION /ALLERGY 2019-2027 ($ MILLION)

FIGURE 3      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY RETINAL DISORDERS 2019-2027 ($ MILLION)

FIGURE 4      NORTH AMERICA RETINAL DISORDERS MARKET BY WET AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)

FIGURE 5      NORTH AMERICA RETINAL DISORDERS MARKET BY DRY AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)

FIGURE 6      NORTH AMERICA RETINAL DISORDERS MARKET BY DIABETIC RETINOPATHY 2019-2027 ($ MILLION)

FIGURE 7      NORTH AMERICA RETINAL DISORDERS MARKET BY OTHER RETINAL DISORDERS 2019-2027 ($ MILLION)

FIGURE 8      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER INDICATION 2019-2027 ($ MILLION)

FIGURE 9      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY PRESCRIPTION DRUGS 2019-2027 ($ MILLION)

FIGURE 10   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OVER-THE-COUNTER DRUGS 2019-2027 ($ MILLION)

FIGURE 11   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY HOSPITAL PHARMACIES 2019-2027 ($ MILLION)

FIGURE 12   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DRUG STORES 2019-2027 ($ MILLION)

FIGURE 13   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ONLINE PHARMACIES 2019-2027 ($ MILLION)

FIGURE 14   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)

FIGURE 15   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY LIQUID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

FIGURE 16   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY SOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

FIGURE 17   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY SEMISOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

FIGURE 18   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS 2019-2027 ($ MILLION)

FIGURE 19   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

FIGURE 20   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-GLAUCOMA 2019-2027 ($ MILLION)

FIGURE 21   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-INFECTIVE 2019-2027 ($ MILLION)

FIGURE 22   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-INFLAMMATORY 2019-2027 ($ MILLION)

FIGURE 23   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY ANTI-ALLERGY 2019-2027 ($ MILLION)

FIGURE 24   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY BIOLOGICS 2019-2027 ($ MILLION)

FIGURE 25   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY CELL THERAPY 2019-2027 ($ MILLION)

FIGURE 26   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY GENE THERAPY 2019-2027 ($ MILLION)

FIGURE 27   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY DRUG DELIVERY 2019-2027 ($ MILLION)

FIGURE 28   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY SMALL MOLECULE 2019-2027 ($ MILLION)

FIGURE 29   NORTH AMERICA OPHTHALMIC DRUGS MARKET BY OTHER TECHNOLOGY 2019-2027 ($ MILLION)

FIGURE 30   THE UNITED STATES POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)

FIGURE 31   THE UNITED STATES OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 32   CANADA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 33   PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016

  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
  1. MARKET BY INDICATION
    • DRY EYE
    • GLAUCOMA
    • INFECTION/INFLAMMATION/ALLERGY
    • RETINAL DISORDERS
      • WET AGE-RELATED MACULAR DEGENERATION
      • DRY AGE-RELATED MACULAR DEGENERATION
      • DIABETIC RETINOPATHY
      • OTHER RETINAL DISORDERS
    • OTHER INDICATION
  2. MARKET BY TYPE
    • PRESCRIPTION DRUGS
    • OVER-THE-COUNTER DRUGS
  3. MARKET BY DISTRIBUTION CHANNEL
    • HOSPITAL PHARMACIES
    • DRUG STORES
    • ONLINE PHARMACIES
    • OTHER DISTRIBUTION CHANNEL
  4. MARKET BY DOSAGE FORM
    • LIQUID OPHTHALMIC DRUG FORMS
    • SOLID OPHTHALMIC DRUG FORMS
    • SEMISOLID OPHTHALMIC DRUG FORMS
    • MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
    • OTHER OPHTHALMIC DRUG FORMS
  5. MARKET BY THERAPEUTIC CLASS
    • ANTI-GLAUCOMA
    • ANTI-INFECTIVE
    • ANTI-INFLAMMATORY
    • ANTI-ALLERGY
  6. MARKET BY TECHNOLOGY
    • BIOLOGICS
    • CELL THERAPY
    • GENE THERAPY
    • DRUG DELIVERY
    • SMALL MOLECULE
    • OTHER TECHNOLOGY

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now